Danaher Corp
DHRQ4 2023(DHR Q3 FY2023)Estimated1% AI
AI Revenue %
1%
AI Fair Value
$703.4M
AI Revenue (Q)
$56.2M
Total Revenue (Q)
$5.6B
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Q3 FY2023 (three-month period ended September 29, 2023). Total sales $6,873M (including E&AS pre-Veralto separation). Segments: Biotechnology $1,664M, Life Sciences $1,706M, Diagnostics $2,254M, Environmental & Applied Solutions $1,249M. No AI revenue disclosure. Filing mentions $36M in separation costs for E&AS (Veralto) but no AI-related disclosures. Conservative 1% for embedded algorithms. Math: ~$69M estimated / $6,873M total = ~1.0%.
Analyzed by claude-opus-4-6
Quoted Figures
Sales $6,873 [three-month period ended September 29, 2023]
10-Q Q3 FY2023, Consolidated Condensed Statements of Earnings
Biotechnology $1,664; Life Sciences $1,706; Diagnostics $2,254; Environmental & Applied Solutions $1,249 [three-month period ended September 29, 2023]
10-Q Q3 FY2023, Note 6 Segment Information
AI Products Identified (Ring 1)
Embedded instrument algorithms (digital pathology, flow cytometry, clinical chemistry)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Biotechnology consumables/bioprocessingLife Sciences instrumentsDiagnostics instrumentsEnvironmental & Applied Solutions
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix